Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplemental Figure 1 - Representative plots for the dose proportionality analysis with a power model: log(AUC) = α + βlog(dose), for SAD/MAD data
Supplemental Figure 2 - Individual and mean CLT/F of BMS-823778 in healthy Japanese subjects grouped
according to (A) UGT1A4 or (B) CYP3A5 genotype (P = 0.38 and 0.71, respectively, when CLT/F
values of subjects with UGT1A4 or CYP3A5 polymorphism were compared to subjects with wild-type genotype)Supplemental Table 1 - Number (Percentage) of Subjects in SAD Study with Laboratory Marked Abnormalities
Supplemental Table 2 - Number (Percentage) of Subjects in MAD Study with Laboratory Marked Abnormalities
Supplemental Table 3 - Number (Percentage) of Subjects in the Chinese Study with Laboratory Marked Abnormalities
Supplemental Table 4 - Number (Percentage) of Subjects in the Japanese Study with Laboratory Marked Abnormalities
In Vitro Assessment of BMS-823778 as an Inducer of Cytochrome P450 Expression in Primary Human Hepatocytes
Supplemental Table 5 - Summary of Enzyme Activity (fold induction) after Treatment with BMS-823778
Supplemental Table 6 - Summary of mRNA Content (fold induction) after Treatment with BMS-823778
- Supplemental Data -